Gareth Lema, MD
Retina Specialist · New York, NYNPI 1982802476
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alimera Sciences, Inc. at 59.1% of the total. Reporting peaked in 2022 at $6,565 and has fallen 90.3% since, to $637 in 2025.
Across 52 payments — averaging $214.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$7K
- Lensar, Inc.$1K
- Bausch & Lomb Americas Inc.$488
- Alcon$390
- Dutch Ophthalmic, USA$379
- AbbVie$342
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$6,10055%
- Food & beverage$5,04845%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 9 | $6,604 |
| Lensar, Inc. | 1 | $1,244 |
| Bausch & Lomb Americas Inc. | 7 | $488 |
| Alcon | 4 | $390 |
| Dutch Ophthalmic, USA | 3 | $379 |
| AbbVie(2 entities) | 4 | $342 |
| Eyepoint US, Inc. | 2 | $250 |
| Novartis | 2 | $216 |
| Ivantis, Inc | 2 | $208 |
| Astellas Pharma US Inc | 4 | $202 |
| Topcon Healthcare, Inc. | 1 | $136 |
| Sight Sciences, Inc. | 1 | $125 |
| Aerie Pharmaceuticals, Inc. | 1 | $124 |
| Apellis Pharmaceuticals, Inc. | 2 | $112 |
| Regeneron | 2 | $92 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $79 |
| ANI Pharmaceuticals, Inc. | 3 | $71 |
| Glaukos Corporation | 1 | $60 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$6,384
- LENSAR LASER SYSTEM$1,244
- YUTIQ$250
- EVA Ophthalmic Surgical System$183
- XEN GLAUCOMA TREATMENT SYSTEM$147
- Hydrus Microstent$129
- OZURDEX$127
- OMNI(R) SURGICAL SYSTEM (US)$125
- SION SURGICAL INSTRUMENT$125
- Rocklatan$124
- Rhopressa$124
- Izervay$122
- BEOVU$122
- EVA, combined machine$105
- TISSUEBLUE$105
- Clareon PanOptix Pro$105
How this compares
$11,167 in reported general payments places this provider in the 75th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 31 | $11,136 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $7,935 |
| Brimonidine Tartrate | 42 | $2,636 |
| Prednisolone Acetate | 39 | $2,200 |
| Difluprednate | 14 | $1,204 |
| Latanoprost | 59 | $408 |
| Dorzolamide Hcl | 31 | $330 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $329 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 23 | $184 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 28 | $133 |
| Ketorolac Tromethamine | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlevro | $216 | $11,13631 claims |
| AbbVieCombigan | $342 | $7,93518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 99 retina specialist providers in New York.
Other retina specialist in New York
- Szilard KissNew York$195K
- Donald D'amicoNew York$109K
- Megan Ridley LaneNew York$11K
- Carl WilkinsNew York$9K
- Gennady LandaNew York$7K
- Joseph TsengNew York$6K
- Ben CohenNew York$5K
- Alan SheymanNew York$4K
- Steven AgemyNew York$3K
- Louis AngiolettiNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.